Concerns are emerging within the executive and board levels overseeing Elon Musk’s companies due to allegations of his drug use, as reported by The Wall Street Journal. Anonymous sources familiar with Musk and his enterprises suggest ongoing use of ketamine, despite Musk claiming to hold a prescription for it as an antidepressant since August of the previous year.
The report details Musk’s alleged history of consuming LSD, cocaine, ecstasy, and psychedelic mushrooms, primarily at private gatherings. In response to these claims, Musk’s lawyer highlighted that the billionaire undergoes regular and random drug testing at SpaceX, consistently passing without any issues.
Elon Musk’s public use of marijuana with podcaster Joe Rogan in 2018 triggered a review of his federal security clearance by the Pentagon, given his role as SpaceX’s CEO. Musk, addressing the allegations on X (formerly Twitter), mentioned that he agreed to three years of random drug testing at NASA’s request after the incident with Rogan, and no trace quantities of any drugs or alcohol were found.
The report also suggests that Tesla director Linda Johnson Rice, in office since 2017, chose not to seek reelection due to frustration with Musk’s behavior and alleged drug use. Elon Musk oversees a diverse portfolio of six companies, including Tesla, SpaceX, X (formerly Twitter), The Boring Co., Neuralink, and xAI, an artificial intelligence startup. The revelation of Musk’s purported drug use adds a layer of scrutiny to the entrepreneur’s leadership across these ventures.
